{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:36:16Z","timestamp":1793907376479,"version":"4.8.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with SLE have an increased risk of comorbidities and impaired survival. We aimed to assess whether various thresholds of oral CS (OCS) can predict development of infections, comorbidities, malignancies and survival in SLE using data from national health registries in Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All incident SLE cases, age &amp;gt;18\u2009years, in Sweden (n\u2009=\u20095309) between 2005 and 2020 and matched population controls (n\u2009=\u200926\u200a545) were included and followed until 2020, a total of 257\u2009942 patient years. Data from national registers were retrieved including information from the National Prescribed Drug Register. Risk factors were analysed using time-dependent Cox regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with no OCS, &amp;gt;0 to &amp;lt;5.0\u2009mg\/day, 5.0\u20137.5\u2009mg\/day as well as &amp;gt;7.5\u2009mg\/day OCS predicted development of infections (pneumonia, influenza, herpes zoster and urinary tract infection), osteoporosis, osteonecrosis, gastroduodenal ulcers, cataracts, hypertension and mortality (all P\u2009&amp;lt;\u20090.05). OCS &amp;gt;0 to &amp;lt;5.0\u2009mg\/day was associated with lower hazard ratios for these comorbidities than higher doses of OCS. Fifteen years after diagnosis, 48% of patients were taking OCS at a median dose of 5.7\u2009mg\/day. A small reduction of OCS treatment 5\u2009years after diagnosis in patients diagnosed with SLE 2006\u201310 compared with 2011\u201315 was observed, 49% vs 46% respectively (P\u2009=\u20090.039).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results highlight the potential harm associated with even low OCS dose treatment in SLE and the need to judiciously use OCS at the lowest possible dose to maximize efficacy and minimize harm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead348","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T10:04:04Z","timestamp":1689242644000},"page":"1104-1112","source":"Crossref","is-referenced-by-count":60,"title":["Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality\u2014a national cohort study"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7522-5069","authenticated-orcid":false,"given":"Martina","family":"Frodlund","sequence":"first","affiliation":[{"name":"Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection\/Rheumatology, Link\u00f6ping University , Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"J\u00f6nsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Rheumatology, Lund University , Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Remkus","sequence":"additional","affiliation":[{"name":"AstraZeneca A\/S , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Telg","sequence":"additional","affiliation":[{"name":"AstraZeneca Nordics , Sodertalje, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"S\u00f6derdahl","sequence":"additional","affiliation":[{"name":"Statisticon AB , Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-7282","authenticated-orcid":false,"given":"Dag","family":"Leonard","sequence":"additional","affiliation":[{"name":"Rheumatology, Department of Medical Sciences, Uppsala University , Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"2024040216340999700_kead348-B1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/joim.12529","article-title":"Systemic lupus erythematosus: still a challenge for physicians","volume":"281","author":"Bengtsson","year":"2017","journal-title":"J Intern Med"},{"key":"2024040216340999700_kead348-B2","doi-asserted-by":"crossref","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"Ronnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2024040216340999700_kead348-B3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/0961203319860198","article-title":"The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts","volume":"28","author":"Frodlund","year":"2019","journal-title":"Lupus"},{"key":"2024040216340999700_kead348-B4","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1177\/0961203319877947","article-title":"Good survival rates in systemic lupus erythematosus in southern Sweden, while the mortality rate remains increased compared with the population","volume":"28","author":"Ingvarsson","year":"2019","journal-title":"Lupus"},{"key":"2024040216340999700_kead348-B5","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1177\/0961203314551083","article-title":"Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study","volume":"23","author":"Lerang","year":"2014","journal-title":"Lupus"},{"key":"2024040216340999700_kead348-B6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0961203314555172","article-title":"Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry","volume":"24","author":"Goncalves","year":"2015","journal-title":"Lupus"},{"key":"2024040216340999700_kead348-B7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/BOR.0000000000000648","article-title":"Malignancies in systemic lupus erythematosus: an update","volume":"31","author":"Ladouceur","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2024040216340999700_kead348-B8","first-page":"613","article-title":"Cervical neoplasia in systemic lupus erythematosus: a nationwide study","volume":"56","author":"Wadstrom","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2024040216340999700_kead348-B9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archinte.1950.00230080003001","article-title":"Observations on the physiologic effects of cortisone and ACTH in man","volume":"85","author":"Sprague","year":"1950","journal-title":"Arch Intern Med (Chic)"},{"key":"2024040216340999700_kead348-B10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s40674-017-0069-8","article-title":"The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?","volume":"3","author":"Stojan","year":"2017","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2024040216340999700_kead348-B11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J Rheumatol"},{"key":"2024040216340999700_kead348-B12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Anna Rheum Dis"},{"key":"2024040216340999700_kead348-B13","doi-asserted-by":"crossref","first-page":"e007769","DOI":"10.1136\/bmjopen-2015-007769","article-title":"Case definitions in Swedish register data to identify systemic lupus erythematosus","volume":"6","author":"Arkema","year":"2016","journal-title":"BMJ Open"},{"key":"2024040216340999700_kead348-B14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/kex444","article-title":"Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort","volume":"57","author":"Little","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024040216340999700_kead348-B15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/0961203311425524","article-title":"Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study","volume":"21","author":"Bengtsson","year":"2012","journal-title":"Lupus"},{"key":"2024040216340999700_kead348-B16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","article-title":"The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis","volume":"60","author":"Pego-Reigosa","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024040216340999700_kead348-B17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12916-016-0673-8","article-title":"Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Singh","year":"2016","journal-title":"BMC Med"},{"key":"2024040216340999700_kead348-B18","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3389\/fimmu.2018.03144","article-title":"The Systemic Lupus Erythematosus Infection Predictive Index (LIPI): a clinical-immunological tool to predict infections in lupus patients","volume":"9","author":"Torres-Ruiz","year":"2018","journal-title":"Front Immunol"},{"key":"2024040216340999700_kead348-B19","first-page":"271","article-title":"Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group","volume":"55","author":"Nived","year":"1985","journal-title":"Q J Med"},{"key":"2024040216340999700_kead348-B20","first-page":"1559","article-title":"Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort","volume":"19","author":"Petri","year":"1992","journal-title":"J Rheumatol"},{"key":"2024040216340999700_kead348-B21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","article-title":"Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus","volume":"47","author":"Rua-Figueroa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024040216340999700_kead348-B22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-84-3-304","article-title":"Glucocorticosteroid therapy: mechanisms of action and clinical considerations","volume":"84","author":"Fauci","year":"1976","journal-title":"Ann Intern Med"},{"key":"2024040216340999700_kead348-B23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0171-2985(80)80065-9","article-title":"Inhibition of granulocyte function by prednisolone and non-steroid anti-inflammatory drugs. Quantitative evaluation with NBT test and its correlation with phagocytosis","volume":"157","author":"Herzer","year":"1980","journal-title":"Immunobiology"},{"key":"2024040216340999700_kead348-B24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13075-022-02869-9","article-title":"Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study","volume":"24","author":"Abe","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2024040216340999700_kead348-B25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2024040216340999700_kead348-B26","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.autrev.2017.09.011","article-title":"Bone mineral density and vitamin D status in systemic lupus erythematosus (SLE): a systematic review","volume":"16","author":"Salman-Monte","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2024040216340999700_kead348-B27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0961203317711012","article-title":"Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors","volume":"27","author":"Gladman","year":"2018","journal-title":"Lupus"},{"key":"2024040216340999700_kead348-B28","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1002\/ctm2.526","article-title":"Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients","volume":"11","author":"Kaneko","year":"2021","journal-title":"Clin Transl Med"},{"key":"2024040216340999700_kead348-B29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3899\/jrheum.160214","article-title":"Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"2024040216340999700_kead348-B30","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10067-013-2214-6","article-title":"Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity","volume":"32","author":"Carli","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2024040216340999700_kead348-B31","doi-asserted-by":"crossref","first-page":"102371","DOI":"10.1016\/j.autrev.2019.102371","article-title":"Systemic lupus erythematosus and hypertension","volume":"18","author":"Munguia-Realpozo","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2024040216340999700_kead348-B32","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s10067-018-4169-0","article-title":"Recognition and control of hypertension, diabetes, and dyslipidemia in patients with systemic lupus erythematosus","volume":"37","author":"Castro","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2024040216340999700_kead348-B33","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024040216340999700_kead348-B34","doi-asserted-by":"crossref","first-page":"e000066","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort","volume":"2","author":"Al Sawah","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2024040216340999700_kead348-B35","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","article-title":"Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus","volume":"53","author":"Ruiz-Arruza","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2024040216340999700_kead348-B36","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024040216340999700_kead348-B37","doi-asserted-by":"crossref","first-page":"860794","DOI":"10.3389\/fonc.2022.860794","article-title":"Association between systemic lupus erythematosus and cancer morbidity and mortality: findings from cohort studies","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"2024040216340999700_kead348-B38","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/ard.2005.036459","article-title":"Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica\/giant cell arteritis","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024040216340999700_kead348-B39","first-page":"620","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2024040216340999700_kead348-B40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.2006.069039","article-title":"The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study","volume":"67","author":"Bernatsky","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2024040216340999700_kead348-B41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3899\/jrheum.170652","article-title":"Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus","volume":"45","author":"Bernatsky","year":"2018","journal-title":"J Rheumatol"},{"key":"2024040216340999700_kead348-B42","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1080\/07853890.2021.1981547","article-title":"Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies","volume":"53","author":"Li","year":"2021","journal-title":"Ann Med"},{"key":"2024040216340999700_kead348-B43","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","article-title":"Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016","volume":"76","author":"Tektonidou","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024040216340999700_kead348-B44","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2024040216340999700_kead348-B45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/rheumatology\/keaa267","article-title":"Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls","volume":"60","author":"Bultink","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024040216340999700_kead348-B46","first-page":"1398","article-title":"High predictive value of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for survival in systemic lupus erythematosus","volume":"29","author":"Nived","year":"2002","journal-title":"J Rheumatol"},{"key":"2024040216340999700_kead348-B47","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/1529-0131(200104)45:2<191::AID-ANR173>3.0.CO;2-2","article-title":"Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort","volume":"45","author":"Alarc\u00f3n","year":"2001","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead348\/50972066\/kead348.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/4\/1104\/57140369\/kead348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/4\/1104\/57140369\/kead348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T14:22:47Z","timestamp":1712067767000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/4\/1104\/7223733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,7,13]]},"published-print":{"date-parts":[[2024,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead348","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2023,7,13]]}}}